{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:56:56Z","timestamp":1793325416655,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.euo.2022.05.005","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T05:10:38Z","timestamp":1655442638000},"page":"505-516","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":93,"title":["Intermediate-risk Non\u2013muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group"],"prefix":"10.1016","volume":"5","author":[{"given":"Wei Shen","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Alfred","family":"Witjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Babjuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trinity J.","family":"Bivalacqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah P.","family":"Psutka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Cookson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Palou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2022.05.005_b0005","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1\u20133 years of maintenance bacillus Calmette-Gu\u00e9rin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2022.05.005_b0010","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2022.05.005_b0015","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2022.05.005_b0020","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ctrv.2016.05.002","article-title":"Management of non-muscle invasive bladder cancer: a comprehensive analysis of guidelines from the United States, Europe and Asia","volume":"47","author":"Tan","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.euo.2022.05.005_b0025","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC Guidelines Panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2022.05.005_b0030","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)\u20142019 update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2022.05.005_b0035","doi-asserted-by":"crossref","first-page":"329","DOI":"10.6004\/jnccn.2020.0011","article-title":"Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology","volume":"18","author":"Flaig","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.euo.2022.05.005_b0040","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2022.05.005_b0045","unstructured":"National Institute for Health and Care Excellence (NICE). Bladder cancer: diagnosis and management. 2015. https:\/\/www.nice.org.uk\/guidance\/ng2\/evidence\/full-guideline-pdf-3744109."},{"key":"10.1016\/j.euo.2022.05.005_b0050","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.juro.2014.02.2573","article-title":"Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer","volume":"192","author":"Kamat","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2022.05.005_b0055","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.euo.2021.11.006","article-title":"Updated European Association of Urology (EAU) prognostic factor risk groups overestimate the risk of progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin","volume":"5","author":"Lobo","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2022.05.005_b0060","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"B\u00f6hle","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2022.05.005_b0065","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/bju.14995","article-title":"Risk-adapted management of low-grade bladder tumours: recommendations from the International Bladder Cancer Group (IBCG)","volume":"125","author":"Matulay","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2022.05.005_b0070","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2015.05.050","volume":"69","author":"Sylvester","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2022.05.005_b0075","first-page":"Cd011935","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin versus mitomycin C for Ta and T1 bladder cancer","volume":"1","author":"Schmidt","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.euo.2022.05.005_b0080","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"Sylvester","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2022.05.005_b0085","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstr\u00f6m","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2022.05.005_b0090","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1464-410X.2009.09153.x","article-title":"A 1-year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non-muscle-invasive bladder cancer","volume":"106","author":"Serretta","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2022.05.005_b0095","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2022.05.005_b0100","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.eururo.2016.01.006","article-title":"Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus bacillus Calmette-Gu\u00e9rin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder Cancer","volume":"69","author":"Arends","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2022.05.005_b0105","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2014.09.026","volume":"67","author":"Solsona","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2022.05.005_b0110","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.eururo.2018.09.020","article-title":"BOXIT\u2014a randomised phase III placebo-controlled trial evaluating the addition of celecoxib to standard treatment of transitional cell carcinoma of the bladder (CRUK\/07\/004)","volume":"75","author":"Kelly","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2022.05.005_b0115","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.eururo.2017.06.038","article-title":"Value of an immediate intravesical instillation of mitomycin C in patients with non\u2013muscle-invasive bladder cancer: a prospective multicentre randomised study in 2243 patients","volume":"73","author":"Bosschieter","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2022.05.005_b0120","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.eururo.2016.03.034","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin versus combination of epirubicin and interferon-\u03b12a in reducing recurrence of non-muscle-invasive bladder carcinoma: FinnBladder-6 study","volume":"70","author":"Marttila","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2022.05.005_b0125","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.eururo.2007.04.062","volume":"52","author":"Ojea","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2022.05.005_b0130","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.eururo.2009.01.006","article-title":"Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study","volume":"55","author":"Gudj\u00f3nsson","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2022.05.005_b0135","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1001\/jama.2018.4657","article-title":"Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non\u2013muscle-invasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial","volume":"319","author":"Messing","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.euo.2022.05.005_b0140","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.eururo.2014.05.033","article-title":"The effect of age on the efficacy of maintenance bacillus Calmette-Gu\u00e9rin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC Genito-urinary Group study 30911","volume":"66","author":"Oddens","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2022.05.005_b0145","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.eururo.2007.02.063","article-title":"Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with bacillus Calmette-Gu\u00e9rin (BCG) in patients with non-muscle-invasive bladder carcinoma","volume":"52","author":"Friedrich","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2022.05.005_b0150","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1464-410X.2010.09891.x","article-title":"Maintenance therapy with bacillus Calmette-Gu\u00e9rin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer","volume":"108","author":"Hinotsu","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2022.05.005_b0155","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ijsu.2018.02.045","article-title":"Maintenance versus non-maintenance intravesical bacillus Calmette-Guerin instillation for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized clinical trials","volume":"52","author":"Chen","year":"2018","journal-title":"Int J Surg"},{"key":"10.1016\/j.euo.2022.05.005_b0160","first-page":"298","article-title":"Effective dose and adverse effects of maintenance Bacillus Calmette-Gu\u00e9rin in intermediate and high risk non-muscle invasive bladder cancer: a meta-analysis of randomized clinical trial","volume":"46","author":"Astram","year":"2014","journal-title":"Acta Med Indones"},{"key":"10.1016\/j.euo.2022.05.005_b0165","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.eururo.2007.12.033","article-title":"Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer","volume":"53","author":"Hendricksen","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2022.05.005_b0170","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.euf.2018.08.019","article-title":"Systematic review on the utilization of maintenance intravesical chemotherapy in the management of non-muscle-invasive bladder cancer","volume":"4","author":"Tabayoyong","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2022.05.005_b0175","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/j.1464-410X.2010.09654.x","article-title":"Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC)","volume":"107","author":"Colombo","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2022.05.005_b0180","doi-asserted-by":"crossref","first-page":"775527","DOI":"10.3389\/fsurg.2021.775527","article-title":"Intravesical chemohyperthermia vs. bacillus Calmette-Guerin instillation for intermediate- and high-risk non-muscle invasive bladder cancer: a systematic review and meta-analysis","volume":"8","author":"Zhao","year":"2021","journal-title":"Front Surg"},{"key":"10.1016\/j.euo.2022.05.005_b0185","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1200\/JCO.2017.35.6_suppl.319","article-title":"Immune response results of vesigenurtacel-l (HS-410) in combination with BCG from a randomized phase II trial in patients with non-muscle invasive bladder cancer (NMIBC)","volume":"35","author":"Steinberg","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2022.05.005_b0190","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00345-015-1598-0","article-title":"Prediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer, including external validation","volume":"34","author":"Lammers","year":"2016","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2022.05.005_b0195","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/JU.0000000000000688","article-title":"Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer","volume":"203","author":"Steinberg","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2022.05.005_b0200","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.eururo.2009.06.028","article-title":"Recurrence and progression of disease in non\u2013muscle-invasive bladder cancer: from epidemiology to treatment strategy","volume":"56","author":"Van Rhijn","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2022.05.005_b0205","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/106689690501300203","article-title":"The 2004 WHO classification of bladder tumors: a summary and commentary","volume":"13","author":"Montironi","year":"2005","journal-title":"Int J Surg Pathol"},{"key":"10.1016\/j.euo.2022.05.005_b0210","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1046\/j.1464-410x.2000.00356.x","article-title":"Clinical significance of interobserver differences in the staging and grading of superficial bladder cancer","volume":"85","author":"Tosoni","year":"2000","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2022.05.005_b0215","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/CU9.0000000000000012","article-title":"Comparison of the clinical usefulness of different urinary tests for the initial detection of bladder cancer: a systematic review","volume":"15","author":"Sciarra","year":"2021","journal-title":"Curr Urol"},{"key":"10.1016\/j.euo.2022.05.005_b0220","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000019859","article-title":"Significance of bladder biopsies in Ta, T1 bladder tumors: a report from the EORTC Genito-Urinary Tract Cancer Cooperative Group","volume":"35","author":"van der Meijden","year":"1999","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2022.05.005_b0225","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.eururo.2013.03.059","article-title":"Photodynamic diagnosis of non\u2013muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data","volume":"64","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2022.05.005_b0230","doi-asserted-by":"crossref","first-page":"e948","DOI":"10.1016\/j.juro.2018.02.2278","article-title":"MP71-14 Frequency of low grade T1 bladder cancer has decreased but continues to vary by institution","volume":"199","author":"Jordan","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2022.05.005_b0235","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.pathol.2020.09.014","article-title":"Stage T1 bladder cancer: diagnostic criteria and pitfalls","volume":"53","author":"Lopez-Beltran","year":"2021","journal-title":"Pathology"},{"key":"10.1016\/j.euo.2022.05.005_b0240","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0022-5347(17)37706-6","article-title":"Stage T1 bladder cancer: grade is the primary determinant for risk of muscle invasion","volume":"146","author":"Kaubisch","year":"1991","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2022.05.005_b0245","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1159\/000052355","article-title":"Proposal for changes in cystoscopic follow-up of patients with low-grade pTa bladder tumor","volume":"37","author":"Oge","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2022.05.005_b0250","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.eururo.2007.10.006","article-title":"Prognostic factors in patients with non\u2013muscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin: multivariate analysis of data from four randomized CUETO trials","volume":"53","author":"Fernandez-Gomez","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2022.05.005_b0255","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1016\/j.celrep.2019.01.095","article-title":"Whole-organ genomic characterization of mucosal field effects initiating bladder carcinogenesis","volume":"26","author":"Majewski","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.euo.2022.05.005_b0260","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.eururo.2013.08.034","article-title":"Long-term cancer-specific outcomes of TaG1 urothelial carcinoma of the bladder","volume":"65","author":"Rieken","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2022.05.005_b0265","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2022.05.005_b0270","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/01.ju.0000076621.71247.6c","article-title":"Expectant management of small, recurrent, noninvasive papillary bladder tumors","volume":"170","author":"Soloway","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2022.05.005_b0275","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(01)61607-0","article-title":"5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group","volume":"161","author":"Malmstr\u00f6m","year":"1999","journal-title":"J Urol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931122000888?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931122000888?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:47:32Z","timestamp":1762876052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931122000888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S2588931122000888"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2022.05.005","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intermediate-risk Non\u2013muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2022.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}